Has Ben George, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,532,882 in general payments to Ben George, MD across 1,018 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ben George, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ben George, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ben George, MD

Medical Oncology · Rochester, MNNPI 1295930519

Payments from drug & device makers

$5,532,882in general payments, 2019–2025

Across 1,018 payments — averaging $5435.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Mirati Therapeutics, Inc.$1.4M
E.r. Squibb & Sons, L.L.C.$930K
Roche Products Limited$780K
Boehringer Ingelheim International GmbH$694K
Genentech, Inc.$689K
Taiho Oncology, Inc.$203K
plus $882K from 32 others

$15,727in research payments, 2019–2025

Across 12 payments — averaging $1310.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$8K
Bristol Myers Squibb$5K
Boehringer Ingelheim$2K
F. Hoffmann-la Roche AG$1K

What the payments were for

Consulting fees$224,85439%
Speaking & faculty fees$298,53152%
Travel & lodging$48,6668%
Food & beverage$6,3571%
Education$990%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Mirati Therapeutics, Inc.	114	$1,354,477
E.r. Squibb & Sons, L.L.C.	35	$929,704
Roche Products Limited	80	$780,052
Boehringer Ingelheim International GmbH	153	$694,293
Genentech, Inc.	120	$688,689
Taiho Oncology, Inc.	107	$203,393
Foundation Medicine, Inc.	48	$192,604
Pfizer	25	$152,231
Daiichi Sankyo Inc.	44	$143,344
Daiichi Sankyo Company LTD	4	$75,327
Ipsen Biopharmaceuticals, Inc	61	$63,924
Astellas Pharma US Inc	39	$50,411
AstraZeneca	26	$41,153
Biontech SE	5	$40,020
Merck	12	$24,970
Boehringer Ingelheim Pharma GmbH & Co.kg	76	$16,504
Eisai Inc.	6	$14,800
F. Hoffmann-la Roche AG	8	$11,681
Takeda Pharmaceuticals U.S.A., Inc.	5	$9,075
Boston Scientific	4	$9,063
Bristol Myers Squibb	7	$7,369
Corcept Therapeutics	7	$6,676
Roche Diagnostics International Ltd	4	$4,242
Beone Medicines USA, Inc.	1	$3,200
Amgen	2	$2,845
Legend Biotech USA Inc.	1	$2,555
Hoffmann-la Roche Limited	1	$2,170
Astellas Pharma Global Development	1	$2,100
Boehringer Ingelheim	1	$1,582
Array Biopharma Inc	2	$1,330
Exelixis Inc.	3	$1,034
Terumo Medical Corporation	2	$930
EMD Serono, Inc.	7	$440
Tempus AI, Inc	2	$243
Genentech USA, Inc.	2	$191
Sirtex Medical Inc	1	$141
Seagen Inc.	1	$99
Ionis Pharmaceuticals, Inc.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,532,882 in reported general payments places this provider in the 90th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$62,782

Medicare patients

117

Services billed

777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ondansetron Hcl	65	$878
Dexamethasone	45	$365
Prochlorperazine Maleate	17	$154

Paid to pharmacies, not to this prescriber.

Other medical oncology in Rochester

Evanthia GalanisRochester$72.3M
Frank SinicropeRochester$10.3M
Harry YoonRochester$10.2M
Konstantinos LeventakosRochester$9.6M
Matthew BlockRochester$8.1M
Keith BibleRochester$7.5M
Jian CampianRochester$7.3M
Katharine PriceRochester$7M
Robert McWilliamsRochester$6.3M
Elisabeth HeathRochester$6.2M

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →